<DOC>
	<DOCNO>NCT00665041</DOCNO>
	<brief_summary>Assess tolerability quinagolide 200 μg/day dose-titration regimen oocyte donor undergo control ovarian hyperstimulation risk develop OHSS Secondary Objectives Estimate effect quinagolide dose-titration regimen compare placebo peritoneal fluid accumulation , incidence ascites , OHSS symptoms clinical laboratory parameter haemoconcentration</brief_summary>
	<brief_title>Tolerability Quinagolide Dose-titration Regimen Oocyte Donors Risk Developing Ovarian Hyperstimulation Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Quinagolide</mesh_term>
	<criteria>1 . Signed Informed Consent Form , prior screen evaluation 2 . In good physical mental health 3 . Premenopausal females age 2134 year ( inclusive ) time randomisation 4 . Body mass index ( BMI ) 18 29 kg/m2 ( inclusive ) 5 . Oocyte donor currently undergo control ovarian hyperstimulation cycle assist reproductive technology ( ART ) 6 . Antral follicle count ≥ 20 1 . Any exclusion criterion oocyte donation 2 . Known clinically significant systemic disease ( e.g. , insulin dependent diabetes ) 3 . Known endocrine metabolic abnormality ( pituitary , adrenal , pancreas , liver kidney ) compromise participation study 4 . Undiagnosed vaginal bleeding 5 . Known tumour ovary , breast , uterus , adrenal gland , pituitary hypothalamus 6 . Malformations sexual organ incompatible pregnancy 7 . Positive pregnancy test prior start stimulation 8 . Treatment dopamine agonist ( ATC code N04BC ) dopamine antagonist ( ATC code N05A ) within 2 month prior randomisation 9 . Treatment hormonal therapy ( except thyroid medication oral contraceptive except routinely use part control ovarian hyperstimulation cycle ) , antipsychotic ( ATC code N05A ) , antidepressant ( ATC code N06 ) , anxiolytic ( ATC code N05B ) , hypnotic sedative ( ATC code N05C ) continuous use prostaglandin inhibitor ( nonsteroid antiinflammatory drug ( NSAIDs ) , include aspirin ) within 2 week prior randomisation 10 . Known hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 11 . Known history psychotic disorder 12 . Hypotension , orthostatic hypotension recurrent syncope within 6 month prior randomisation 13 . Ongoing treatment hypertension 14 . Known previous poor tolerability dopamine agonists 15 . Known impaired hepatic renal function 16 . Current past ( 12 month prior randomisation ) abuse alcohol drug , and/or current ( last month prior randomisation ) use alcohol ( 14 unit per week ) 17 . Current past ( 3 month prior randomisation ) smoking habit 20 cigarette per day 18 . History chemotherapy ( except gestational condition ) radiotherapy 19 . Use investigational drug 3 month prior randomisation 20 . Previous participation study 21 . Hypersensitivity active substance excipients</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>